kl1333
Small moleculeexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2017 (NCT03056209)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)C1=NC2=C(N1)C(=O)C(=O)C3=C2C=CC=C3- Mol. weight
- 240.2573 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSNA2ZOL5UGM ↗
- ChEMBLCHEMBL4594430 ↗
Also known as
- kl1333
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05650229 | Phase 2 | Dec 31, 2022 | Abliva, Harvard University, Newcastle University |
| NCT04643249 | Phase 1 | Nov 10, 2020 | Abliva |
| NCT03888716 | Phase 1 | Mar 18, 2019 | Abliva |
| NCT03056209 | Phase 1 | Mar 1, 2017 | KT&G Corporation, Yungjin Pharm. Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abliva | For profit | 3 | 3 | 2 | 2019 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| KT&G Corporation | For profit | 1 | 1 | 1 | 2017 |
| Newcastle University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Yungjin Pharm. Co., Ltd. | For profit | 1 | 0 | 1 | 2017 |
5 organizations
Page 1 / 1